pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor
Daiichi Sankyo US
Daiichi Sankyo
Daiichi Sankyo US is a pharma organization headquartered in basking ridge, USA. Primary therapeutic focus areas include Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor, No medical conditio
211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US HQ
4,386 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
- Employees
- 4,386
- Programs
- 58
- Drugs
- 66
- Patents
- 0
DS8201-724
Phase 3 · small molecule · Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer
DS8201-724 for Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer is a Phase 3 program (small_molecule) at Daiichi Sankyo with 1 ClinicalTrials.gov record(s).
Internal code DS8201-724
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Daiichi Sankyo
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer
- Status
- active
- Trials
- 1